Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Engineering broadly neutralizing antibodies for HIV prevention and therapy.

Hua CK, Ackerman ME.

Adv Drug Deliv Rev. 2016 Aug 1;103:157-73. doi: 10.1016/j.addr.2016.01.013. Epub 2016 Jan 29. Review.

2.

Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.

Jacob RA, Moyo T, Schomaker M, Abrahams F, Grau Pujol B, Dorfman JR.

J Virol. 2015 May;89(10):5264-75. doi: 10.1128/JVI.00129-15. Epub 2015 Feb 11.

3.

Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections.

Wagh K, Seaman MS, Zingg M, Fitzsimons T, Barouch DH, Burton DR, Connors M, Ho DD, Mascola JR, Nussenzweig MC, Ravetch J, Gautam R, Martin MA, Montefiori DC, Korber B.

PLoS Pathog. 2018 Mar 5;14(3):e1006860. doi: 10.1371/journal.ppat.1006860. eCollection 2018 Mar.

4.

Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes.

Kong R, Louder MK, Wagh K, Bailer RT, deCamp A, Greene K, Gao H, Taft JD, Gazumyan A, Liu C, Nussenzweig MC, Korber B, Montefiori DC, Mascola JR.

J Virol. 2015 Mar;89(5):2659-71. doi: 10.1128/JVI.03136-14. Epub 2014 Dec 17.

5.

New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency.

Doria-Rose NA, Bhiman JN, Roark RS, Schramm CA, Gorman J, Chuang GY, Pancera M, Cale EM, Ernandes MJ, Louder MK, Asokan M, Bailer RT, Druz A, Fraschilla IR, Garrett NJ, Jarosinski M, Lynch RM, McKee K, O'Dell S, Pegu A, Schmidt SD, Staupe RP, Sutton MS, Wang K, Wibmer CK, Haynes BF, Abdool-Karim S, Shapiro L, Kwong PD, Moore PL, Morris L, Mascola JR.

J Virol. 2015 Oct 14;90(1):76-91. doi: 10.1128/JVI.01791-15. Print 2016 Jan 1.

6.

Use of broadly neutralizing antibodies for HIV-1 prevention.

Pegu A, Hessell AJ, Mascola JR, Haigwood NL.

Immunol Rev. 2017 Jan;275(1):296-312. doi: 10.1111/imr.12511. Review.

7.

Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies.

Zhang Z, Li S, Gu Y, Xia N.

Int J Mol Sci. 2016 Nov 18;17(11). pii: E1901. Review.

8.

Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System.

Bhiman JN, Lynch RM.

Curr HIV/AIDS Rep. 2017 Apr;14(2):54-62. doi: 10.1007/s11904-017-0352-1. Review.

9.

Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor.

Pegu A, Yang ZY, Boyington JC, Wu L, Ko SY, Schmidt SD, McKee K, Kong WP, Shi W, Chen X, Todd JP, Letvin NL, Huang J, Nason MC, Hoxie JA, Kwong PD, Connors M, Rao SS, Mascola JR, Nabel GJ.

Sci Transl Med. 2014 Jul 2;6(243):243ra88. doi: 10.1126/scitranslmed.3008992.

10.

Towards HIV-1 remission: potential roles for broadly neutralizing antibodies.

Halper-Stromberg A, Nussenzweig MC.

J Clin Invest. 2016 Feb;126(2):415-23. doi: 10.1172/JCI80561. Epub 2016 Jan 11. Review.

11.

Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments.

Hraber P, Rademeyer C, Williamson C, Seaman MS, Gottardo R, Tang H, Greene K, Gao H, LaBranche C, Mascola JR, Morris L, Montefiori DC, Korber B.

J Virol. 2017 Sep 12;91(19). pii: e00991-17. doi: 10.1128/JVI.00991-17. Print 2017 Oct 1. Erratum in: J Virol. 2017 Dec 14;92 (1):.

12.
13.

Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.

Cohen YZ, Lorenzi JCC, Seaman MS, Nogueira L, Schoofs T, Krassnig L, Butler A, Millard K, Fitzsimons T, Daniell X, Dizon JP, Shimeliovich I, Montefiori DC, Caskey M, Nussenzweig MC.

J Virol. 2018 Feb 12;92(5). pii: e01883-17. doi: 10.1128/JVI.01883-17. Print 2018 Mar 1.

14.

Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.

Li H, Zony C, Chen P, Chen BK.

J Virol. 2017 Apr 13;91(9). pii: e02425-16. doi: 10.1128/JVI.02425-16. Print 2017 May 1.

15.

Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo.

Rudicell RS, Kwon YD, Ko SY, Pegu A, Louder MK, Georgiev IS, Wu X, Zhu J, Boyington JC, Chen X, Shi W, Yang ZY, Doria-Rose NA, McKee K, O'Dell S, Schmidt SD, Chuang GY, Druz A, Soto C, Yang Y, Zhang B, Zhou T, Todd JP, Lloyd KE, Eudailey J, Roberts KE, Donald BR, Bailer RT, Ledgerwood J; NISC Comparative Sequencing Program, Mullikin JC, Shapiro L, Koup RA, Graham BS, Nason MC, Connors M, Haynes BF, Rao SS, Roederer M, Kwong PD, Mascola JR, Nabel GJ.

J Virol. 2014 Nov;88(21):12669-82. doi: 10.1128/JVI.02213-14. Epub 2014 Aug 20.

16.

Evolution of broadly cross-reactive HIV-1-neutralizing activity: therapy-associated decline, positive association with detectable viremia, and partial restoration of B-cell subpopulations.

Ferreira CB, Merino-Mansilla A, Llano A, Pérez I, Crespo I, Llinas L, Garcia F, Gatell JM, Yuste E, Sanchez-Merino V.

J Virol. 2013 Nov;87(22):12227-36. doi: 10.1128/JVI.02155-13. Epub 2013 Sep 4.

17.

Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies.

von Bredow B, Arias JF, Heyer LN, Moldt B, Le K, Robinson JE, Zolla-Pazner S, Burton DR, Evans DT.

J Virol. 2016 Jun 10;90(13):6127-6139. doi: 10.1128/JVI.00347-16. Print 2016 Jul 1.

18.

HIV broadly neutralizing antibody targets.

Wibmer CK, Moore PL, Morris L.

Curr Opin HIV AIDS. 2015 May;10(3):135-43. doi: 10.1097/COH.0000000000000153. Review.

19.

Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes.

Wibmer CK, Bhiman JN, Gray ES, Tumba N, Abdool Karim SS, Williamson C, Morris L, Moore PL.

PLoS Pathog. 2013 Oct;9(10):e1003738. doi: 10.1371/journal.ppat.1003738. Epub 2013 Oct 31.

20.

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.

Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP Jr, Buckley N, Kremer G, Nogueira L, Braunschweig M, Scheid JF, Horwitz JA, Shimeliovich I, Ben-Avraham S, Witmer-Pack M, Platten M, Lehmann C, Burke LA, Hawthorne T, Gorelick RJ, Walker BD, Keler T, Gulick RM, Fätkenheuer G, Schlesinger SJ, Nussenzweig MC.

Nature. 2015 Jun 25;522(7557):487-91. doi: 10.1038/nature14411. Epub 2015 Apr 8. Erratum in: Nature. 2016 Jul 28;535(7613):580.

Supplemental Content

Support Center